1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/55213
Full metadata record
DC FieldValueLanguage
dc.creatorBruno Silva Andradept_BR
dc.creatorFernanda de Souza Rangelpt_BR
dc.creatorNaiane Oliveira Santospt_BR
dc.creatorAndria Dos Santos Freitaspt_BR
dc.creatorWagner Rodrigues de Assis Soarespt_BR
dc.creatorSergio Siqueirapt_BR
dc.creatorDebmalya Barhpt_BR
dc.creatorAristóteles Góes Netopt_BR
dc.creatorAlexander Birbrairpt_BR
dc.creatorVasco Ariston de Carvalho Azevedopt_BR
dc.date.accessioned2023-06-21T20:05:00Z-
dc.date.available2023-06-21T20:05:00Z-
dc.date.issued2020-
dc.citation.volume11pt_BR
dc.identifier.doihttps://doi.org/10.3389/fphar.2020.590598pt_BR
dc.identifier.issn1663-9812pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/55213-
dc.description.resumoThe SARS-CoV-2 outbreak originally appeared in China in December 2019 and became a global pandemic in March 2020. This infectious disease has directly affected public health and the world economy. Several palliative therapeutic treatments and prophylaxis strategies have been used to control the progress of this viral infection, including pre-(PrEP) and post-exposure prophylaxis. On the other hand, research groups around the world are still studying novel drug prophylaxis and treatment using repurposing approaches, as well as vaccination options, which are in different pre-clinical and clinical testing phases. This systematic review evaluated 1,228 articles from the PubMed and Scopus indexing databases, following the Kitchenham bibliographic searching protocol, with the aim to list drug candidates, potentially approved to be used as new options for SARS-CoV-2 prophylaxis clinical trials and medical protocols. In searching protocol, we used the following keywords: “Covid-19 or SARS-CoV-2” or “Coronavirus or 2019 nCoV,” “prophylaxis,” “prophylactic,” “pre-exposure,” “COVID-19 or SARS-CoV-2 Chemoprophylaxis,” “repurposed,” “strategies,” “clinical,” “trials,” “anti-SARS-CoV-2,” “anti-covid-19,” “Antiviral,” “Therapy prevention in vitro,” in cells “and” human testing. After all protocol steps, we selected 60 articles that included: 15 studies with clinical data, 22 studies that used in vitro experiments, seven studies using animal models, and 18 studies performed with in silico experiments. Additionally, we included more 22 compounds between FDA approved drugs and drug-like like molecules, which were tested in large-scale screenings, as well as those repurposed approved drugs with new mechanism of actions. The drugs selected in this review can assist clinical studies and medical guidelines on the rational repurposing of known antiviral drugs for COVID-19 prophylaxis.pt_BR
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Geraispt_BR
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorpt_BR
dc.description.sponsorshipOutra Agênciapt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentICB - DEPARTAMENTO DE MICROBIOLOGIApt_BR
dc.publisher.departmentICB - DEPARTAMENTO DE PATOLOGIApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofFrontiers in Pharmacologypt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectSARS-CoV-2pt_BR
dc.subjectProphylaxispt_BR
dc.subjectAntiviralpt_BR
dc.subjectDrug repurposingpt_BR
dc.subjectCOVID-19pt_BR
dc.subject.otherSARS-CoV-2pt_BR
dc.subject.otherAntiviraispt_BR
dc.subject.otherReposicionamento de Medicamentospt_BR
dc.subject.otherCOVID-19pt_BR
dc.titleRepurposing approved drugs for guiding COVID-19 Prophylaxis: a systematic reviewpt_BR
dc.title.alternativeReaproveitamento de medicamentos aprovados para orientar a profilaxia da COVID-19: uma revisão sistemáticapt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.frontiersin.org/articles/10.3389/fphar.2020.590598/fullpt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-8031-9454pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-5138-9042pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-9041-9777pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-9254-6550pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-2557-7768pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-7692-6243pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis_ A Systematic Review.pdf12.85 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.